|
First DMARD
| | |
Treatment at 1 year
| | | |
|---|
|
Type
|
N
|
Delay between RA onset and DMARD start (weeks)a
| |
N
|
DAS28(ESR)-4v at baseline
|
DAS28(ESR)-4v at 1 year
|
|---|
|
Methotrexateb
|
335
|
26.7 ± 11.6 (24.3)
|
Methotrexate
|
302
|
5.3 ± 1.3 (5.2)
|
3.2 ± 2.7 (3.0)
|
| | |
35 ± 15.3 (39.4)
|
Other synthetic DMARD(s)c
|
19
|
5.3 ± 1.4 (5.3)
|
4.1 ± 1.5 (4.1)
|
| | |
30.5 ± 0.7 (21.6)
|
Biologic agentd
|
11
|
5.7 ± 0.4 (5.5)
|
3.9 ± 0.9 (4.2)
|
|
Leflunomide
|
35
|
48.9 ± 11.6 (46.9)
|
Methotrexate
|
9
|
5.8 ± 1.3 (5.6)
|
4.0 ± 2.7 (2.9)
|
| | |
22.5 ± 15.3 (20.7)
|
Other synthetic DMARD(s)
|
24
|
5.4 ± 1.4 (5.5)
|
3.3 ± 1.5 (3.0)
|
| | |
37.8 ± 0.7 (37.8)
|
Biologic agentd
|
2
|
5.9 ± 0.4 (5.9)
|
4.2 ± 0.9 (4.2)
|
- Data are mean ± SD (median). aDelay between RA onset and DMARD start (weeks) (P = 0.479): Methotrexate: 27.2 ± 15.1 (24.7); Leflunomide: 30.1 ± 18.1 (24.6); bat one year: one patient did not receive any DMARDs and data for two patients were not available; cleflunomide or salazopyrine; dadalinumab, etanercept, infliximab or anakinra. DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; N, number.
